Website Managed & Supported By:
|
|
|
|
|
|
VBWG LITERATURE UPDATES
|
|
|
|
Myocardial infarction accelerates atherosclerosis
Survival after a first myocardial infarction approaches 90%. However, re-infarction occurs commonly and has a high mortality. Nahrendorf and colleagues tested the hypothesis that a first infarct‐triggering a burst of acute systemic inflammation aimed at repair of the injured heart‐could accelerate atherosclerosis. They showed that the systemic response to ischaemic injury aggravates chronic atherosclerosis.
Nahrendorf M et al.
Nature. 2012; 487: 325-329
|
|
|
|
|
|
MicroRNAs in age-related diseases
MicroRNAs (miRNAs) are implicated in the pathogenesis of various cardiovascular and neurological diseases and have become an intriguing target for therapeutic intervention. An array of animal and human miRNA-based therapeutic studies has been performed, validating miRNAs as being successfully targetable to treat a wide range of diseases.
Dimmeler S, Nicotera P
EMBO Mol Med (2013) 5, 180-190
|
|
|
|
|
|
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells.
To elucidate the mechanisms underlying hypertrophic cardiomyopathy (HCM) development, Dr. Wu and colleagues generated patient-specific induced pluripotent stem cell cardiomyocytes from a ten-member family cohort carrying a hereditary HCM missense mutation in the MYH7 gene. They showed there is a clear association between the presence of the MYH7 mutation and cell hypertrophy and modifications in calcium cycling. Pharmacological restoration of Ca(2+) homeostasis prevented development of hypertrophy and electrophysiological irregularities.
Wu JC, et al.
Cell Stem Cell 2013; 12 (1): 101-113
|
|
|
|
|
|
|
|
|
|
|
RELAX-AHF: Serelaxin improves symptoms, reduces CV mortality by 37%
Results of the RELAX-AHF study showed that in patients with acute heart failure, serelaxin, recombinant human relaxin-2, significantly improves symptoms of heart failure and clinical outcomes.
Teerlink JR, et al, for the RELAXin Acute Heart Failure (RELAX-AHF) investigators
Lancet 2013; 381(9860): 29-39
|
|
|
|
|
VBWG ONLINE LECTURES
|
|
|
|
|
|
|
|
